CN103054884B - Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof - Google Patents
Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof Download PDFInfo
- Publication number
- CN103054884B CN103054884B CN201110315901.6A CN201110315901A CN103054884B CN 103054884 B CN103054884 B CN 103054884B CN 201110315901 A CN201110315901 A CN 201110315901A CN 103054884 B CN103054884 B CN 103054884B
- Authority
- CN
- China
- Prior art keywords
- fructus forsythiae
- forsythiae ester
- ester glycoside
- preparation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention belongs to the field of Chinese medicines, disclose Fructus Forsythiae ester glycoside at the purposes prepared in against parainfluenza virus medicine and preparation thereof.In Fructus Forsythiae ester glycoside treatment respiratory virus infection body of the present invention, pharmacodynamics test research shows, Fructus Forsythiae ester glycoside has obvious inhibitory action to parainfluenza virus.
Description
Technical field
The invention belongs to the field of Chinese medicines, specifically, the present invention relates to Fructus Forsythiae ester glycoside at the application prepared in against parainfluenza virus medicine and preparation thereof.
Background technology
Fructus Forsythiae ester glycoside (Forsythoside A) is the effective ingredient extracted from Oleaceae forsythia Fructus Forsythiae (Fructus Forsythiae).Be using phillyrin as the index investigating Fructus Forsythiae extraction process in the past, in recent years along with going deep into of studying Active Ingredients of Forsythia Suspensa, find that phillyrin is without antiviral activity, what play antiviral activity is Fructus Forsythiae ester glycoside.And the content of forsythiaside A is the highest in Fructus Forsythiae ester glycoside, and performance antivirus action is nearly all forsythiaside A, but forsythiaside A is difficult to independent stable existence again, therefore traditionally, often the Fructus Forsythiae ester glycoside effective constituents containing forsythiaside A is called Fructus Forsythiae ester glycoside.The structural formula of Fructus Forsythiae ester glycoside (A) is as follows:
Antipyretic for Fructus Forsythiae ester glycoside, antiinflammatory, enhancing immunity and effect that is antibacterial and antiviral etc., existing bibliographical information both at home and abroad, such as, Liu Donglei etc. are studied (Dong-Lei Liu to the effect of Fructus Forsythiae ester glycoside enhancing immunity, Yang Zhang, Sui-Xu Xul, et al.Phenylethanoid Glycosides fromForsythia suspensaVahl.Journal of ChinesePharmaceutical Sciences 1998, 7 (2): 103-105), disclose the application of Fructus Forsythiae ester glycoside in this field, result shows: along with the increase of Fructus Forsythiae ester glycoside concentration, the Splenic vein hemodynamics of ConA induction increases, show that Fructus Forsythiae ester glycoside has the effect strengthening immunity, Hooke outstanding persons etc. are studied (see Hooke outstanding person etc. to Fructus Forsythiae ester glycoside antiviral effect in vitro, the experimentation of forsythoside antiviral effect in vitro, China's Chinese medicine science and technology, 2001 vol.8 No.2:89), result shows, Fructus Forsythiae ester glycoside has certain inhibitory action, infected by influenza Type A3 (Fa3) and parainfluenza virus type III (PF3) unrestraint effect to syncytial virus, adenovirus type III and 7 types and Coxsackievirus B3 and 7 types, Feng Shuyi etc. are studied (see Feng Shuyi etc. to Fructus Forsythiae ester glycoside infection and refrigeration function, Fructus Forsythiae ester glycoside infection, refrigeration function are studied, modern biology is in progress, 2006 vol.6 No.10:73), result shows, and Fructus Forsythiae ester glycoside has obvious antagonism to the infection of gram negative bacteria as escherichia coli, bacillus pyocyaneus and caused by Staphylococcus aureus.
In technical research in the past, applicant has obtained the process extracting high-purity forsythin, and declare multinomial Chinese invention patent and obtain the authorization, as ZL200610027024.1, ZL200610027036.4, ZL200610027037.9 and ZL200610029080.9 and ZL200610148179.0, above patented technology can make Fructus Forsythiae ester glycoside effective ingredient purity reach more than 90%.Meanwhile, applicant is antibacterial to Fructus Forsythiae ester glycoside, antiviral activity has carried out deeply systematically studying, and declared two Chinese invention patents, title is " application of high-purity forsythin in antibacterial, the antiviral of preparation and other medicines " (CN200710094089.2) and " purposes of forsythiaside A in preparation treatment hepatitis B medicament " (CN200810208209.1) respectively, and all obtains the authorization.
But prior art does not relate to the application of Fructus Forsythiae ester glycoside in preparation against parainfluenza virus medicine.
Summary of the invention
The object of this invention is to provide the novelty teabag of Fructus Forsythiae ester glycoside in pharmacy, be specifically related to the purposes of Fructus Forsythiae ester glycoside in preparation against parainfluenza virus medicine.Fructus Forsythiae ester glycoside involved in the present invention refers to that extract from forsythia by various method, that purity is more than 90% high-purity forsythin monomer.
The present invention, by pharmacodynamics test research in Fructus Forsythiae ester glycoside treatment respiratory virus infection body, investigates the drug action of Fructus Forsythiae ester glycoside against parainfluenza virus.
In Fructus Forsythiae ester glycoside treatment respiratory virus infection body, results of pharmacodynamic test shows:
After adopting parainfluenza virus I type (PIV-1) infecting mouse, mouse lung index obviously increases, and infects and starts to give Fructus Forsythiae ester glycoside the same day, continuous 4 days, 3 dosage groups all have obvious therapeutical effect to the pneumonia of infecting mouse, and have good dose-effect positive correlation.
Another object of the present invention is the preparation of the Fructus Forsythiae ester glycoside being provided for against parainfluenza virus, namely contains with Fructus Forsythiae ester glycoside the preparation of the against parainfluenza virus being effective ingredient.It is characterized in that being that effective ingredient is equipped with pharmaceutic adjuvant and makes injection, oral liquid and capsule by pharmaceutically conventional preparation method with Fructus Forsythiae ester glycoside.Pharmacodynamics test shows, each preparation of Fructus Forsythiae ester glycoside of the present invention has the effect of obvious against parainfluenza virus.
Preferably, described injection is lyophilized injectable powder or injection.
Preparation containing Fructus Forsythiae ester glycoside involved in the present invention is achieved through the following technical solutions:
1) Fructus Forsythiae ester glycoside crude drug, pharmaceutic adjuvant disodiumedetate are got in the preparation of injection, Homogeneous phase mixing, by the pharmaceutically conventional method preparing injection, be prepared into injection, the percentage composition controlling Fructus Forsythiae ester glycoside weight/volume in injection is 5%-20%.
2) Fructus Forsythiae ester glycoside crude drug, pharmaceutic adjuvant sorbitol, glucose are got in the preparation of freeze-dried powder, Homogeneous phase mixing, by the pharmaceutically conventional method preparing injection, be prepared into injection or lyophilized injectable powder, the percentage composition controlling Fructus Forsythiae ester glycoside weight/volume in freeze-dried powder is 5%-20%.
3) preparation of oral liquid
Get Fructus Forsythiae ester glycoside crude drug pharmaceutic adjuvant sucrose, sodium benzoate, Homogeneous phase mixing, by the pharmaceutically conventional method preparing oral liquid, prepare oral liquid.Controlling Fructus Forsythiae ester glycoside weight/volume percentage composition in oral liquid is 2%-15%.
4) preparation of capsule
Get Fructus Forsythiae ester glycoside crude drug, pharmaceutic adjuvant dextrin, Homogeneous phase mixing, by the pharmaceutically conventional method preparing capsule, be prepared into capsule.Controlling Fructus Forsythiae ester glycoside weight percentage in capsule is 2%-15%.
Detailed description of the invention
Below in conjunction with specific embodiment, set forth the present invention further.These embodiments are interpreted as only being not used in for illustration of the present invention limiting the scope of the invention.After the content of having read the present invention's record, those skilled in the art can make various changes or modifications the present invention.
Pharmacodynamics test in embodiment 1 Fructus Forsythiae ester glycoside treatment respiratory virus infection body
One, test objective
Investigate Fructus Forsythiae ester glycoside and be used for the treatment of the effectiveness of respiratory virus infection, for the development of Fructus Forsythiae ester glycoside, exploitation and clinical practice provide foundation.
Two, test site
Institute Of Chinese Materia Medica Of China Academy of Chinese Medical Sciences ABSL-2 biocontainment laboratory.
Three, test material
3.1 test medicine
Fructus Forsythiae ester glycoside, is provided by Shanghai Yusen New Medicine Development Co., Ltd, lot number: 090801, date received: 2010.07.12, effect duration: tentative 2 years; Content: 94%, character: buff powder, dissolubility: soluble in water, condition of storage: seal 4 DEG C of refrigerators.
3.2 positive control drug
3.2.1 ribavirin injection: Tianjin Pharmaceutical Jiaozuo Co., Ltd.'s product, the date of manufacture: 2009.11.07, lot number: 09110711, valid until in October, 2011; Character: colourless clear liquid, specification: 100mg/ml, indication: for treatment and the prevention of influenza, clinical people's usage and dosage: 1g/60/kg/d intravenous drip.
3.2.2 QINKAILING ZHUSHEYE: Pharmaceutical Factory of Beijing University of Chinese Medicine produces, batch number: 912403A, and the date of manufacture: 2009.06.25, valid until on June 24th, 2011; Character: brown color clear liquid, specification: 10ml/ props up, function cures mainly: heat-clearing and toxic substances removing, eleminating phlegm and freeing channels, consciousness-restoring and orifice-opening, be used for the treatment of calentura, upper respiratory tract infection etc., the clinical usage and dosage of people: 40ml/60/kg/d intravenous drip.
3.3 experimental animal
3.3.1ICR mice and BALB/C mice (SPF/VAF level), male and female dual-purpose, tieing up experimental animal Technology Co., Ltd. of tonneau China by Beijing provides, animal licence: SCXK (capital) 2006-0009.Interior resisting virus body weight is 14 ± 1g.
3.4 virus stain
Parainfluenza virus I type (PIV-1), purchased from China Sickness Prevention Control Center Virus Disease Prevention Control Institute's influenza room, this room routine passage ,-80 DEG C of Refrigerator stores.
3.5 test reagent
Ether, Beijing Reagent Company product, lot number: 20090707; 99% ethanol is commercially available analytical pure.
3.6 test apparatus
CO
2incubator, Japanese Yamato science strain formula can manufacture; Inverted microscope, Germany produces Olympus board; HC-3018R High speed refrigerated centrifuge, good Products in middle section; A2 type Biohazard Safety Equipment, model: MSC1.8, German Thermo product; The weight of animals electronic balance, model: YP/0001, Shanghai Yue Ping scientific instrument company limited product; Animal viscera electronic balance, model: AR1140, U.S. Chaus product; IVC Mouse feeder cage, Suzhou teaching Long Ju factory product; Thermister, 715 types that Shanghai Medical Instrument and Meter Factory produces.
Four, test method and result
4.1 dose design
4.11 Fructus Forsythiae ester glycosides: according to medicine efficacy screening result of the test in early stage, this experimental study small mouse consumption is respectively 400mg/kg/d, 200mg/kg/d, 100mg/kg/d, is equivalent to 2 times of people's quantity, equimultiple and 1/2 times respectively.
4.1.2 ribavirin injection: quantity is 1g/60kg/d, being converted into mice dose,equivalent is 183mg/kg/d.
4.1.3 QINKAILING ZHUSHEYE: quantity is 40ml/60kg/d, being converted into mice dose,equivalent is 7.33ml/kg/d.
4.2 Antiviral assay in vivo
4.2.1 parainfluenza virus I type (PIV-1) is infected to the therapeutical effect of BALB/C mice pulmonary inflammation model
Get BALB/C mice and be divided into 7 groups at random by body weight grade, be respectively Normal group, model control group, ribavirin matched group, QINGKAILING matched group, Fructus Forsythiae ester glycoside 3 dosage groups, often organize 10.Except Normal group, mice is used ether light anesthesia, (parainfluenza virus is with 1000 LD for the infection of virus liquid collunarium
50), every 35ul.Infect and started administration the same day, press 0.1ml/10g lumbar injection, every day 1 time, continuous 4 days, Normal group and model control group be normal saline lumbar injection under equal conditions at every turn.Dissect after within 5th day, weighing, claim lung weight, calculate Lung Exponent and lung index.Compare one factor analysis of variance between result employing group and carry out statistical procedures (the results are shown in Table 4).
Lung Exponent=lung weight in wet base (g)/body weight (g)
The therapeutical effect of table 4 pair viral infection BALB/C mice pulmonary inflammation model
Note: compare ##P < 0.01 with normal group; Compare with model control group,
*p < 0.01,
*p < 0.05
Table 4 result shows: after adopting parainfluenza virus I type (PIV-1) infecting mouse, mouse lung index obviously increases, and compares have significant difference (P < 0.01) with Normal group; Infect and started to give the same day after Fructus Forsythiae ester glycoside treats 4 days, 3 tested dosage group Lung Exponent all have and reduce in various degree, and parainfluenza virus 3 dosage groups and model control group more all have significant difference (P < 0.05, P < 0.01).And there is good dose-effect positive correlation.
Six, conclusion
Fructus Forsythiae ester glycoside has obvious inhibitory action to parainfluenza virus in vivo.
The preparation of embodiment 2 freeze-dried powder
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 50g, glucose 50g, sorbitol 150g mixes, inject and use water 1000ml, be stirred to dissolve, citric acid-sodium hydrogen phosphate buffer salt regulates pH to be 5.0, with 0.22 μm of microporous filter membrane aseptic filtration, then use 8000 dalton's ultrafilter membrane depyrogenations; Through intermediate after the assay was approved, supply volume with water for injection, be distributed into 1000, put household freezer, by following freeze-drying curve lyophilizing and get final product.
| Temperature (DEG C) | Time (h) |
| 0--40 | 2 |
| -40 | 4 |
| -40--25 | 3 |
| -25 | 5 |
| -25-30 | 2 |
| 30 | 9 |
The preparation of embodiment 3 freeze-dried powder
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 75g, glucose 60g, sorbitol 130g mix, and inject and use water 1000ml, be stirred to dissolve, citric acid-sodium hydrogen phosphate buffer salt regulates pH to be 5.0, with 0.22 μm of microporous filter membrane aseptic filtration, then uses 8000 dalton's ultrafilter membrane depyrogenations; Through intermediate after the assay was approved, supply volume with water for injection, be distributed into 1000, put household freezer, by the freeze-drying curve lyophilizing shown in embodiment 1 and get final product.
The preparation of embodiment 4 freeze-dried powder
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 90g, glucose 40g, sorbitol 160g mix, and inject and use water 1000ml, be stirred to dissolve, citric acid-sodium hydrogen phosphate buffer salt regulates pH to be 5.0, with 0.22 μm of microporous filter membrane aseptic filtration, then uses 8000 dalton's ultrafilter membrane depyrogenations; Through intermediate after the assay was approved, supply volume with water for injection, be distributed into 1000, put household freezer, by the freeze-drying curve lyophilizing shown in embodiment 1 and get final product.
The preparation of embodiment 5 freeze-dried powder
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 120g, glucose 50g, sorbitol 125g mix, and inject and use water 1000ml, be stirred to dissolve, citric acid-sodium hydrogen phosphate buffer salt regulates pH to be 5.0, with 0.22 μm of microporous filter membrane aseptic filtration, then uses 8000 dalton's ultrafilter membrane depyrogenations; Through intermediate after the assay was approved, supply volume with water for injection, be distributed into 1000, put household freezer, by the freeze-drying curve lyophilizing shown in embodiment 1 and get final product.
The preparation of embodiment 6 freeze-dried powder
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 200g, glucose 50g, sorbitol 110g mix, and inject and use water 1000ml, be stirred to dissolve, citric acid-sodium hydrogen phosphate buffer salt regulates pH to be 5.0, with 0.22 μm of microporous filter membrane aseptic filtration, then uses 8000 dalton's ultrafilter membrane depyrogenations; Through intermediate after the assay was approved, supply volume with water for injection, be distributed into 1000, put household freezer, by the freeze-drying curve lyophilizing shown in embodiment 1 and get final product.
The preparation of embodiment 7 injection
Prescription:
Preparation technology: add 2.5 grams of disodiumedetates and stir in water for injection, dissolve completely; Add the active carbon that full dose is 0.05% of 1000ml, stir, filter, carbon removal; Add 50 grams of Fructus Forsythiae ester glycosides to make it to dissolve completely, add citric acid-phosphate sodium dihydrogen buffer solution and regulate pH to 5.0, add the active carbon that full dose is 0.02% of 1000ml, stirring at room temperature, filter carbon removal, in filtrate, mend the 5000ml that adds to the full amount of water for injection, measure pH, after content is qualified, repeatedly be filtered to clear and bright, be packed as 100, sterilizing, packaging, to obtain final product.
The preparation of embodiment 8 injection
Prescription:
Preparation technology: add 2.5 grams of disodiumedetates and stir in water for injection, dissolve completely; Add the active carbon that full dose is 0.05% of 1000ml, stir, filter, carbon removal; Add 80 grams of Fructus Forsythiae ester glycosides to make it to dissolve completely, add citric acid-phosphate sodium dihydrogen buffer solution and regulate pH to 5.0, add the active carbon that full dose is 0.02% of 1000ml, stirring at room temperature, filter carbon removal, in filtrate, mend the 5000ml that adds to the full amount of water for injection, measure pH, after content is qualified, repeatedly be filtered to clear and bright, be packed as 100, sterilizing, packaging, to obtain final product.
The preparation of embodiment 9 injection
Prescription:
Preparation technology: add 2.5 grams of disodiumedetates and stir in water for injection, dissolve completely; Add the active carbon that full dose is 0.05% of 1000ml, stir, filter, carbon removal; Add 120 grams of Fructus Forsythiae ester glycosides to make it to dissolve completely, add citric acid-phosphate sodium dihydrogen buffer solution and regulate pH to 5.0, add the active carbon that full dose is 0.02% of 1000ml, stirring at room temperature, filter carbon removal, in filtrate, mend the 5000ml that adds to the full amount of water for injection, measure pH, after content is qualified, repeatedly be filtered to clear and bright, be packed as 100, sterilizing, packaging, to obtain final product.
The preparation of embodiment 10 injection
Prescription:
Preparation technology: add 2.5 grams of disodiumedetates and stir in water for injection, dissolve completely; Add the active carbon that full dose is 0.05% of 1000ml, stir, filter, carbon removal; Add 200 grams of Fructus Forsythiae ester glycosides to make it to dissolve completely, add citric acid-phosphate sodium dihydrogen buffer solution and regulate pH to 5.0, add the active carbon that full dose is 0.02% of 1000ml, stirring at room temperature, filter carbon removal, in filtrate, mend the 5000ml that adds to the full amount of water for injection, measure pH, after content is qualified, repeatedly be filtered to clear and bright, be packed as 100, sterilizing, packaging, to obtain final product.
The preparation of embodiment 11 oral liquid
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 20 grams, be dissolved in the purified water of 1000ml, purified water is added to preparing total amount after adding 150 grams of sucrose and 2 grams of sodium benzoate stirring and dissolving again, be filtered to the qualified rear fill 100 of clarity, specification is that 10ml/ props up, 100 DEG C of flowing steam sterilizations 60 minutes, pack and get final product.
The preparation of embodiment 12 oral liquid
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 60 grams, be dissolved in the purified water of 1000ml, purified water is added to preparing total amount after adding 150 grams of sucrose and 2 grams of sodium benzoate stirring and dissolving again, be filtered to the qualified rear fill 100 of clarity, specification is that 10ml/ props up, 100 DEG C of flowing steam sterilizations 60 minutes, pack and get final product.
The preparation of embodiment 13 oral liquid
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 100 grams, be dissolved in the purified water of 1000ml, purified water is added to preparing total amount after adding 150 grams of sucrose and 2 grams of sodium benzoate stirring and dissolving again, be filtered to the qualified rear fill 100 of clarity, specification is that 10ml/ props up, 100 DEG C of flowing steam sterilizations 60 minutes, pack and get final product.
The preparation of embodiment 14 oral liquid
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 130 grams, be dissolved in the purified water of 1000ml, purified water is added to preparing total amount after adding 150 grams of sucrose and 2 grams of sodium benzoate stirring and dissolving again, be filtered to the qualified rear fill 100 of clarity, specification is that 10ml/ props up, 100 DEG C of flowing steam sterilizations 60 minutes, pack and get final product.
The preparation of embodiment 15 oral liquid
Prescription:
Preparation technology: get Fructus Forsythiae ester glycoside 150 grams, be dissolved in the purified water of 1000ml, purified water is added to preparing total amount after adding 150 grams of sucrose and 2 grams of sodium benzoate stirring and dissolving again, be filtered to the qualified rear fill 100 of clarity, specification is that 10ml/ props up, 100 DEG C of flowing steam sterilizations 60 minutes, pack and get final product.
The preparation of embodiment 16 capsule
Prescription:
Fructus Forsythiae ester glycoside 7g
Dextrin 345g
Preparation technology: get Fructus Forsythiae ester glycoside 7 grams, adds 345 grams, dextrin, mixing, and dry granulation, incapsulates, and makes 1000, and packaging, to obtain final product.
The preparation of embodiment 17 capsule
Prescription:
Fructus Forsythiae ester glycoside 15g
Dextrin 340g
Preparation technology: get Fructus Forsythiae ester glycoside 15 grams, adds 340 grams, dextrin, mixing, and dry granulation, incapsulates, and makes 1000, and packaging, to obtain final product.
The preparation of embodiment 18 capsule
Prescription:
Fructus Forsythiae ester glycoside 28g
Dextrin 325g
Preparation technology: get Fructus Forsythiae ester glycoside 28 grams, adds 325 grams, dextrin, mixing, and dry granulation, incapsulates, and makes 1000, and packaging, to obtain final product.
The preparation of embodiment 19 capsule
Prescription:
Fructus Forsythiae ester glycoside 45g
Dextrin 310g
Preparation technology: get Fructus Forsythiae ester glycoside 45 grams, adds 310 grams, dextrin, mixing, and dry granulation, incapsulates, and makes 1000, and packaging, to obtain final product.
The preparation of embodiment 20 capsule
Prescription:
Fructus Forsythiae ester glycoside 52.5g
Dextrin 305g
Preparation technology: get Fructus Forsythiae ester glycoside 52.5 grams, adds 305 grams, dextrin, mixing, and dry granulation, incapsulates, and makes 1000, and packaging, to obtain final product.
Claims (6)
1. the purposes of that extract from forsythia, that purity is more than a 90% Fructus Forsythiae ester glycoside monomer in preparation against parainfluenza virus I type medicine.
2. purposes according to claim 1, is characterized in that, described medicine is that effective ingredient is equipped with adjuvant with Fructus Forsythiae ester glycoside, makes injection, oral liquid and capsule by pharmaceutically conventional preparation method.
3. purposes according to claim 2, is characterized in that, described injection is freeze-dried powder or injection.
4. purposes according to claim 3, is characterized in that, the weight/volume percentage composition of described Fructus Forsythiae ester glycoside in freeze-dried powder or injection is 5%-20%.
5. purposes according to claim 2, is characterized in that, the weight/volume percentage composition of described Fructus Forsythiae ester glycoside in oral liquid is 2%-15%.
6. purposes according to claim 2, is characterized in that, the weight percentage of described Fructus Forsythiae ester glycoside in capsule is 2%-15%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110315901.6A CN103054884B (en) | 2011-10-18 | 2011-10-18 | Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110315901.6A CN103054884B (en) | 2011-10-18 | 2011-10-18 | Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103054884A CN103054884A (en) | 2013-04-24 |
| CN103054884B true CN103054884B (en) | 2015-11-04 |
Family
ID=48097980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110315901.6A Active CN103054884B (en) | 2011-10-18 | 2011-10-18 | Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103054884B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209255A (en) * | 2006-12-28 | 2008-07-02 | 上海玉森新药开发有限公司 | Forsythiaside injection preparations and preparation thereof |
| CN101390869A (en) * | 2007-09-19 | 2009-03-25 | 上海玉森新药开发有限公司 | Use of high-purity forsythin in preparing bacteriostasis, antivirus and other medicine |
| CN101757006A (en) * | 2008-12-25 | 2010-06-30 | 上海玉森新药开发有限公司 | Application of forsythiaside A in preparing hepatitis B therapeutic drug |
| WO2011080593A2 (en) * | 2009-12-30 | 2011-07-07 | Purapharm International (Hk) Limited | Materials and methods for prevention and treatment of viral infections |
-
2011
- 2011-10-18 CN CN201110315901.6A patent/CN103054884B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209255A (en) * | 2006-12-28 | 2008-07-02 | 上海玉森新药开发有限公司 | Forsythiaside injection preparations and preparation thereof |
| CN101390869A (en) * | 2007-09-19 | 2009-03-25 | 上海玉森新药开发有限公司 | Use of high-purity forsythin in preparing bacteriostasis, antivirus and other medicine |
| CN101757006A (en) * | 2008-12-25 | 2010-06-30 | 上海玉森新药开发有限公司 | Application of forsythiaside A in preparing hepatitis B therapeutic drug |
| WO2011080593A2 (en) * | 2009-12-30 | 2011-07-07 | Purapharm International (Hk) Limited | Materials and methods for prevention and treatment of viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103054884A (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102114044B (en) | Artificially processed bear bile powder and preparation method thereof | |
| CN111040006A (en) | Extraction method of bilberry glycoside and application of bilberry glycoside | |
| CN101983632A (en) | Compound Tilmicosin nanoemulsion antibacterial agent and preparation method thereof | |
| WO2013071696A1 (en) | Use of five normal bases in humans for preparation of tumour drugs | |
| CN103054884B (en) | Fructus Forsythiae ester glycoside is at the purposes prepared in against parainfluenza virus medicine and preparation thereof | |
| CN103054885A (en) | Application of Forsythoside A in preparation of anti-influenza A H1N1 virus medicine and preparation thereof | |
| CN103705474B (en) | Lyophilized pharmaceutical composition containing omeprazole sodium | |
| CN102266567B (en) | Radix scutellariae extractive phospholipid complex, and preparation method and purpose thereof | |
| CN114699436A (en) | Traditional Chinese medicine extract composition for preventing and treating influenza as well as preparation method and application thereof | |
| CN103520182A (en) | Pharmaceutical composition for treating liver fibrosis and preparation method of pharmaceutical composition | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN100546573C (en) | A kind of anti-infective medicament composition and preparation method thereof | |
| CN102920718B (en) | The application of phenylethanoid glycoside monomeric compound | |
| CN102526038A (en) | Temozolomide brain-targeting pharmaceutical composition and application thereof | |
| CN100425229C (en) | Local medicine preparation containing antiinfective medicine composition and its preparing method | |
| CN102526714B (en) | Medicine composition for curing tumour and preparation method thereof | |
| CN106806418A (en) | A kind of swap buffers Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN1939413B (en) | Compound douricien medicinal composition | |
| CN106138152A (en) | The new application of Flos Chrysanthemi Indici | |
| CN103690496B (en) | Freeze-drying medicine composition containing sodium ozagrel | |
| CN103054886A (en) | Application of Forsythoside A in preparation of anti-herpes simplex virus medicine and preparation thereof | |
| CN1939325B (en) | Medicinal composition of houttuynin sodium and astragalin, its making method and usage | |
| CN107334754A (en) | A kind of Qing kailing Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN102552180B (en) | Clindamycin phosphate composition liensinine freeze-dried powder and preparation method thereof | |
| CN1939380B (en) | Heat-clearing analgesic medicinal composition with anti-infective and antiviral functions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210118 Address after: 201203 Room 401, building 2, 351 GuoShouJing Road, Pudong New Area, Shanghai Patentee after: SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION Co.,Ltd. Address before: 276005 No. 209 Hongqi Road, Lanshan District, Linyi City, Shandong Province Patentee before: Lunan Pharmaceutical Group Corp. Effective date of registration: 20210118 Address after: 215123 C30 / F, Biological Nanotechnology Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee after: SUZHOU YOUSEEN NEW DRUG R & D Co.,Ltd. Address before: 201203 Room 401, building 2, 351 GuoShouJing Road, Pudong New Area, Shanghai Patentee before: SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION Co.,Ltd. |
|
| TR01 | Transfer of patent right |